| Cell proliferation markers and growth factors in ovarian cancer. | |
| | |
MedLine Citation:
|
PMID: 7742006 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Results from our studies on the clinical applicability of proliferation markers and growth factors in the histopathological assessment of malignancy and prognosis of ovarian neoplasms are presented. Bromodeoxyuridine incorporation, Ki 67 antigen visualization and proliferation cell nuclear antigen expression indicated location and extent of cell proliferation, though not uniformly as compared to flow cytometry and mitotic counting. Clinicopathological correlations of the occurrence of programmed cell death, apoptosis, as indicated by morphology gave inconclusive results, as did analysis of Bcl-2 expression. Increased visualization of p53 protein was associated with increased degree of malignancy but was inconsistent in individual specimens. Growth factor expression, in particular transforming growth factor beta staining intensity, gave additional information on cell behaviour as did vascular endothelial growth factor distribution on vascularization and vessel neoformation when compared to platelet derived growth factor expression, useful in isolated specimens, and to basic fibroblast growth factor expression. The markers presented are indispensible in certain tumour types and give additional information improving our understanding of ovarian neoplasms and tumour classification in general but are mostly not yet reliable enough for clinically applicable conclusions of individual patients. |
| | |
Authors:
|
T Jussila; F Stenbäck |
Related Documents
:
|
1645356 - Insulin-induced mitogenesis associated with transformation by the sv40 large t antigen. 2819836 - What's new in receptor mediated growth promotion of normal and malignant cells? 21735336 - Human cell-conditioned media produced under embryonic-like conditions result in improve... 1732036 - Many growth factors may not be growth factors. 412856 - Thermal transitions in the adhesiveness of hela cells: effects of cell growth, trypsin ... 20393126 - Potential and flux landscapes quantify the stability and robustness of budding yeast ce... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Annals of medicine Volume: 27 ISSN: 0785-3890 ISO Abbreviation: Ann. Med. Publication Date: 1995 Feb |
Date Detail:
|
Created Date: 1995-06-14 Completed Date: 1995-06-14 Revised Date: 2005-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8906388 Medline TA: Ann Med Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 87-94 Citation Subset: IM |
Affiliation:
|
Department of Pathology, University of Oulu, Finland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Apoptosis Cell Division Endothelial Growth Factors / analysis Female Fibroblast Growth Factors / analysis Growth Substances / analysis* Humans Immunohistochemistry Ki-67 Antigen Lymphokines / analysis Neoplasm Proteins / analysis Nuclear Proteins / analysis Ovarian Neoplasms / metabolism*, pathology* Platelet-Derived Growth Factor / analysis Proliferating Cell Nuclear Antigen / analysis* Proto-Oncogene Proteins Proto-Oncogene Proteins c-bcl-2 Transforming Growth Factor beta / analysis Tumor Markers, Biological / analysis Tumor Suppressor Protein p53 / analysis Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors |
| Chemical | |
Reg. No./Substance:
|
0/Endothelial Growth Factors; 0/Growth Substances; 0/Ki-67 Antigen; 0/Lymphokines; 0/Neoplasm Proteins; 0/Nuclear Proteins; 0/Platelet-Derived Growth Factor; 0/Proliferating Cell Nuclear Antigen; 0/Proto-Oncogene Proteins; 0/Proto-Oncogene Proteins c-bcl-2; 0/Transforming Growth Factor beta; 0/Tumor Markers, Biological; 0/Tumor Suppressor Protein p53; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors; 62031-54-3/Fibroblast Growth Factors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: CSF-1 and its receptor in ovarian, endometrial and breast cancer.
Next Document: Primary surgery in ovarian cancer: current opinions.